Akston Biosciences CorporationIs a company specializing in the development of new classes of biologics and has announced positive results from Phase I trials of Covid-19 vaccine candidates. An open-label study of AKS-452, a room temperature-stable vaccine, a protein subunit, was conducted in 60 subjects and was found to be generally well tolerated. In addition, 100% conversion was obtained with a single dose regimen of 90 micrograms and a double dose regimen of 45 micrograms and 90 micrograms. Later this month, the University of Groningen Medical Center in the Netherlands is planning a phase II trial with both single- and double-dose regimens.It will be processed by Tracer Europe, A contract research institute specializing in fast-track clinical trials.
Pfizer And BioNTech We have provided the latest information on a comprehensive booster strategy for addressing the circular mutation of Covid-19. The two companies found positive data in an ongoing booster immune trial, including a third dose of the current BNT162b2 Covid-19 vaccine. Initial data indicate that booster immunization given 6 months after the second dose of vaccine has a consistent tolerability profile and produces high neutralizing titers for wild-type and beta mutants. Suggests. Additional data also suggest that immune sera obtained immediately after the second dose of vaccine have a strong neutralizing titer against delta mutants in laboratory studies.
According to the results of an interim study of a recent REACT-1 study, the Covid-19 infection rate of double-vaccinated people under the age of 65 is one-third that of unvaccinated people in the same age group. .. The results of the Imperial College London and Ipsosmori surveys from June 24th to July 5th show that infections have quadrupled to 170 people since the last REACT-1 study from May 20th to June 7th. One person has been infected, indicating that the recent doubling time is 6 days. Between June 24th and July 5th, more than 47,000 volunteers performed PCR tests in the United Kingdom to determine the infection rate of the general population. The prevalence of two vaccinations under the age of 65 was 0.35%, compared to 1.15% of the same age group who were not vaccinated at all, indicating the impact of vaccination development. The study also found that infections were increasing in all regions, but in London it was up to eight times higher.
https://www.pharmaceutical-technology.com/uncategorised/coronavirus-company-news-summary-akston-biosciences-announces-positive-phase-i-results-for-its-covid-19-vaccine-candidate-pfizer-and-biontech-provide-update-on-covid-19-vaccine-booster-pro/ Coronavirus Company News Summary-Akston Biosciences Announces Phase I Positive Results for Covid-19 Vaccine Candidates